"Her-Vaxx can take over the Merck's avelumab market with its superior results."
Avelumab has no market share as it failed its phase 3 trial against HER2+ gastric cancers. Imugene are doing Merck and Pfizer just as big a favour partnering with them as they are through partnering with Imugene. There will hopefully be an opportunity for Avelumab to be used in a HER2+ cancer setting and hopefully that will lead to a fair and equitable licencing agreement that is extremely beneficial to all partners.
Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer, page-167
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.4¢ |
Change
-0.002(2.73%) |
Mkt cap ! $389.5M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.6¢ | 5.3¢ | $443.4K | 8.165M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 1096807 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 807865 | 13 |
View Market Depth
| Last trade - 15.58pm 12/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |